Whitney P. Kirschbrown

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

Antoinette R. Tan, Seock‐Ah Im, André Mattar et al. · The Lancet Oncology · 2020 · 149 citations

Breast Oncology, Oncology, Pharmacology +6

Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study

Nancy U. Lin, Mark D. Pegram, Solmaz Sahebjam et al. · Journal of Clinical Oncology · 2021 · 92 citations · Full text

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors

Anthony W. Tolcher, Patricia LoRusso, Jennifer A. Arzt et al. · Cancer Chemotherapy and Pharmacology · 2015 · 65 citations

Medicine, Pharmacology, Advanced Solid Tumors +5

Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure‐response analysis

Suresh Agarwal, Sathej Gopalakrishnan, Sven Mensing et al. · Hematological Oncology · 2019 · 41 citations

Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors

Angelica Quartino, Hanbin Li, Whitney P. Kirschbrown et al. · Cancer Chemotherapy and Pharmacology · 2018 · 36 citations · Full text